By collaborating with U.S. software developer Palantir Technologies of Palo Alto, California and the Stanford Graduate School of Business and entering into three further agreements with U.S. partners, we are opening up new business opportunities and strengthening its position as an innovation-based science and technology company.
The partnership with Palantir allows our company to use Palantir’s advanced data analytics capabilities to more rapidly develop and deliver medicines and commercialize new products to achieve better patient outcomes. Initially we will apply Palantir’s technology to cancer treatment, particularly in the following areas: the development of a collaborative data and analytics platform for high-precision drug development processes, the analysis of data to better understand therapeutic efficacy, and the creation of a platform for better global supply chain forecasting.
By cooperating with the Stanford Graduate School of Business (Stanford GSB), our company is adding a new module on innovation and digitalization to the curriculum of its internal company university. Our executives will receive advanced training in these subject areas through lectures and practical lessons with teaching staff from Stanford GSB.
The partnerships were officially sealed in January 2017 during a visit by our Executive Board to Silicon Valley. Likewise in January, we signed a licensing agreement with Vertex Pharmaceuticals (Boston) to develop new approaches in cancer therapy, entered into a collaboration agreement with the University of Texas MD Anderson Cancer Center (Houston) covering the use of a research platform, and acquired BioControl Systems (Seattle), a global leader in food safety testing.